Research Analysts’ Weekly Ratings Updates for Healthpeak Properties (DOC)

Healthpeak Properties (NYSE: DOC) recently received a number of ratings updates from brokerages and research firms:

• 6/24/2026 – Healthpeak Properties had its price target raised by JPMorgan Chase & Co. from $18.00 to $21.00. They now have a “neutral” rating on the stock.
• 6/17/2026 – Healthpeak Properties is now covered by Raymond James Financial, Inc.. They set a “market perform” rating on the stock.
• 6/15/2026 – Healthpeak Properties had its price target raised by BMO Capital Markets from $20.00 to $24.00. They now have an “outperform” rating on the stock.
• 6/11/2026 – Healthpeak Properties had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $22.00 price target on the stock, up from $20.00.
• 6/1/2026 – Healthpeak Properties had its price target raised by Wells Fargo & Company from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
• 5/27/2026 – Healthpeak Properties had its price target raised by Scotiabank from $19.00 to $21.00. They now have a “sector perform” rating on the stock.
• 5/22/2026 – Healthpeak Properties had its price target raised by Morgan Stanley from $18.00 to $20.00. They now have an “overweight” rating on the stock.
• 5/14/2026 – Healthpeak Properties had its price target raised by Royal Bank Of Canada from $20.00 to $21.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Healthpeak Properties had its price target raised by UBS Group AG from $17.00 to $19.00. They now have a “neutral” rating on the stock.
• 5/13/2026 – Healthpeak Properties had its price target raised by Robert W. Baird from $19.00 to $21.00. They now have an “outperform” rating on the stock.
• 5/12/2026 – Healthpeak Properties had its price target raised by Citigroup Inc. from $17.50 to $20.00. They now have a “neutral” rating on the stock.
• 5/11/2026 – Healthpeak Properties was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $21.00 price target on the stock.
• 5/10/2026 – Healthpeak Properties was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Healthpeak Properties was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.

Healthpeak Properties Announces Dividend

The business also recently disclosed a monthly dividend, which was paid on Friday, June 26th. Shareholders of record on Monday, June 15th were issued a $0.1017 dividend. The ex-dividend date was Monday, June 15th. This represents a c) annualized dividend and a yield of 5.6%. Healthpeak Properties’s dividend payout ratio is 381.25%.

Insider Buying and Selling

In other news, insider Scott R. Bohn sold 10,989 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total value of $213,736.05. Following the completion of the sale, the insider directly owned 7,636 shares of the company’s stock, valued at approximately $148,520.20. This trade represents a 59.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.23% of the company’s stock.

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.